Profile data is unavailable for this security.
About the company
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-15.08m
- Incorporated2012
- Employees5.00
- LocationIntensity Therapeutics Inc61 Wilton Road, 3Rd FloorWESTPORT 06880United StatesUSA
- Phone+1 (203) 221-7381
- Fax+1 (302) 636-5454
- Websitehttps://www.intensitytherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Angion Biomedica Corp | 0.00 | -38.66m | 54.84m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -87.94m | 55.14m | 51.00 | -- | 0.5838 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Prenetics Global Ltd | 22.25m | -49.97m | 55.28m | 320.00 | -- | 0.2413 | -- | 2.48 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 55.45m | 49.00 | -- | 1.24 | -- | 684.63 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 55.48m | 58.00 | -- | 0.4503 | -- | 6.60 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 55.69m | 151.00 | -- | 0.6471 | -- | 1.07 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Celularity Inc | 22.77m | -196.30m | 56.28m | 120.00 | -- | 1.21 | -- | 2.47 | -11.29 | -11.29 | 1.30 | 2.11 | 0.0836 | 2.90 | 2.39 | 189,758.30 | -72.04 | -19.19 | -94.47 | -20.99 | 29.66 | -- | -862.04 | -454.79 | 0.2086 | 1.37 | 0.4893 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 56.57m | 110.00 | -- | -- | -- | 57.93 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Enzo Biochem Inc | 33.34m | -17.55m | 57.12m | 179.00 | -- | 0.8237 | -- | 1.71 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Aileron Therapeutics Inc | 0.00 | -25.22m | 57.41m | 15.00 | -- | 1.02 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 57.43m | 5.00 | -- | 10.70 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 58.18m | 210.00 | -- | -- | -- | 1.13 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Mural Oncology PLC | 0.00 | -173.30m | 58.78m | 117.00 | -- | 0.2855 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Intensity Therapeutics Inc's reporting currency: US Dollar USD
11.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sapient Capital LLCas of 30 Jun 2024 | 1.01m | 7.34% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 204.98k | 1.49% |
| Brown Advisory LLCas of 30 Jun 2024 | 157.53k | 1.14% |
| Sigma Planning Corp.as of 30 Jun 2024 | 47.87k | 0.35% |
| Geode Capital Management LLCas of 30 Jun 2024 | 47.62k | 0.35% |
| Mesirow Financial Investment Management, Inc.as of 30 Jun 2024 | 44.18k | 0.32% |
| William Blair Investment Management LLCas of 30 Jun 2024 | 37.81k | 0.28% |
| One Charles Private Wealth Services LLCas of 30 Jun 2024 | 31.80k | 0.23% |
| Bison Wealth LLCas of 30 Jun 2024 | 17.42k | 0.13% |
| HRT Financial LLCas of 30 Jun 2024 | 15.86k | 0.12% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
